MedPage today reported on the struggles that some biotechs face as they develop antibiotics.
The article featured news from the recent World AMR Congress and noted that several speakers at the event “cited potential solutions such as the PASTEUR Act in the U.S., a pilot incentive program in the European Union, and the work of the international AMR Action Fund.” The article also featured AMR Action Fund CIO Martin Heidecker, who explained that it is not uncommon for a biotech to run out of money while trying to develop new antibiotics. Read the full article here.
